Donald Trump threatens copper, pharma tariffs: Who will they hurt?

Former President Donald Trump announced new tariffs, including a 50% levy on imported copper effective late July/early August and an immediate 20% tariff on pharmaceuticals, escalating to 200% within a year, aiming to reshore domestic production. Copper futures surged over 12% to a record high on supply disruption concerns, while major drugmaker stocks saw slight declines. The US's significant reliance on imports for both sectors, particularly from Chile for copper and India/China for pharmaceutical ingredients, raises concerns about potential supply chain disruptions and higher consumer costs, though market reaction has been notably calmer compared to previous tariff announcements.

Analysis

The proposed imposition of a 50% tariff on imported copper and a phased 20% to 200% tariff on pharmaceuticals represents a significant escalation in trade protectionism aimed at reshoring domestic production. The market reaction has been sector-specific and pronounced: copper futures surged over 12% to a record high, reflecting the United States' acute vulnerability as it imports nearly half of its refined copper, primarily from non-Chinese sources like Chile (65%). With only two primary domestic smelters and higher production costs compared to China, the US faces a structural deficit that these tariffs could exacerbate, leading to severe supply disruptions for key industries such as electric vehicles and defense. In the pharmaceutical sector, the slight decline in the stocks of Eli Lilly, Merck, and Pfizer underscores the industry's heavy reliance on foreign supply chains; the US imports almost half its active pharmaceutical ingredients (APIs), largely from India and China, and 40% of its finished drugs. Experts warn that reshoring API production could take years and faces significant hurdles, including a lack of trained personnel and infrastructure, suggesting that the immediate impact would be higher costs for consumers. Despite these direct impacts, the broader market has remained relatively calm, a phenomenon attributed to the "TACO theory" (Trump Always Chickens Out), suggesting investors are becoming desensitized and may be pricing in a potential policy reversal before the August 1 deadline.

Key Decisions for Investors

• Investors should anticipate continued upward pressure and volatility on copper prices, presenting a potential opportunity for long positions in copper futures or equities of producers not directly impacted by US tariffs, while downstream industries reliant on copper face significant margin risk.
• Re-evaluate exposure to large pharmaceutical companies like Eli Lilly, Merck, and Pfizer, as their heavy reliance on imported APIs and finished goods from regions like India and China makes them vulnerable to margin compression and supply chain disruptions from the proposed tariffs.
• Monitor political rhetoric and policy developments closely leading up to the August 1 deadline, as the market's belief in the 'TACO theory' suggests a potential for a policy reversal, which could create short-term trading opportunities to fade the initial tariff-driven price moves in affected assets.
• Consider long-term investment themes in domestic manufacturing and supply chain resilience, as these tariffs, regardless of their final implementation, signal a strong political push towards onshoring critical production in sectors like pharmaceuticals and base metals.